Consistent with Wu et al. [57], this study suggests IL-4 treatment in Group A mice reduces parasitaemia, promotes survival, and potentially mitigates experimental cerebral malaria, thereby extending lifespan. This evidence concerns the gene IL4 and cerebral malaria.